Trial Profile

A Phase II Trial of Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Adenoid cystic carcinoma; Carcinoma; Salivary gland cancer; Sarcoma; Squamous cell cancer
Focus Therapeutic Use

04 Jun 2024 Interim Results (n=19) assessing safety and efficacy of of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 According to 59th Annual Meeting of the American Society of Clinical Oncology, first subject received treatment in Nov. 2022.
06 Jun 2023 According to trial design, The time point for the primary analyses is Q3.2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com